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Abstract
Background: Glucose modulates b-cell mass and function through an initial depolarization and Ca
2+ influx, which then
triggers a number of growth regulating signaling pathways. One of the most important downstream effectors in Ca
2+
signaling is the calcium/Calmodulin activated serine threonine phosphatase, calcineurin. Recent evidence suggests that
calcineurin/NFAT is essential for b-cell proliferation, and that in its absence loss of b-cells results in diabetes. We
hypothesized that in contrast, activation of calcineurin might result in expansion of b-cell mass and resistance to diabetes.
Methodology/Principal Findings: To determine the role of activation of calcineurin signaling in the regulation of pancreatic
b-cell mass and proliferation, we created mice that expressed a constitutively active form of calcineurin under the insulin
gene promoter (caCn
RIP). To our surprise, these mice exhibited glucose intolerance. In vitro studies demonstrated that while
the second phase of Insulin secretion is enhanced, the overall insulin secretory response was conserved. Islet morphometric
studies demonstrated decreased b-cell mass suggesting that this was a major component responsible for altered Insulin
secretion and glucose intolerance in caCn
RIP mice. The reduced b-cell mass was accompanied by decreased proliferation and
enhanced apoptosis.
Conclusions: Our studies identify calcineurin as an important factor in controlling glucose homeostasis and indicate that
chronic depolarization leading to increased calcineurin activity may contribute, along with other genetic and environmental
factors, to b-cell dysfunction and diabetes.
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Introduction
The normal response of pancreatic islet b-cells to various
conditions associated with Insulin resistance is to increase the mass
of Insulin producing cells. Plasma glucose concentration is an
important factor in this response and mediates increases in
glucose-induced islet b-cell growth and proliferation [1,2,3,4]. In
contrast, chronic elevation in plasma glucose, so called glucotoxi-
city, can have deleterious effects on b-cell function and survival
[5,6,7,8,9,10,11,12,13]. On the other hand, glucose starvation
negatively affects b-cell survival [13,14,15]. The explanation for
the different responses to glucose levels is unclear but changes in
intracellular Ca
2+ concentrations play an important role. The idea
that chronically elevated intracellular Ca
2+ concentrations due to
high glucose can result in deleterious effects on b-cell proliferation,
survival and/or function is consistent with the Ca
2+ set-point
hypothesis described in the neuronal literature [16]. This concept
states that very low or high intracellular Ca
2+ levels are
incompatible with survival and that between these extremes,
Ca
2+ concentrations have protective and physiological effects on
neuronal function.
Increase in intracellular Ca
2+ by glucose and depolarizing
agents activates several intracellular pathways including, Ca
2+/
Calmodulin kinases (CaMK) and extracellular signal-regulated
protein kinases (ERK1 and ERK2) and calcineurin among others
[17,18,19,20,21]. Calcineurin is the only serine/threonine protein
phosphatase under the direct control of intracellular Ca
2+ and
plays a critical role in coupling Ca
2+ signals to cellular responses
[22]. Therefore, calcineurin is a major candidate to mediate
signals activated by glucose-induced depolarization and Ca
2+
influx. Calcineurin is a heterodimer containing a catalytic/
Calmodulin-binding subunit, calcineurin A, tightly bound to a
calcineurin phosphatase regulatory Ca
2+-binding subunit, calci-
neurin b1 (Cnb1) [22]. Calcineurin is an important regulator of
multiple biological functions, but very few studies have investigat-
ed its role in pancreatic b-cells. Elegant experiments by Heit, et. al.
demonstrated a role for this signaling pathway in regulation of b-
cell growth and function [23]. These studies showed that mice with
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result of decreased b-cell mass, proliferation and insulin content
[23]. This phenotype was associated with decreases in critical
genes necessary for b-cell development and function including,
ins1, ins2, glut2, mafA, pdx1, beta2 and cyclin D2. Interestingly, the
metabolic phenotype and altered gene expression were restored by
conditional expression of active NFATc1 in cnb1-deficient b-cells
[23]. Nuclear factor of activated T cells (NF-AT) is one of the most
recognized calcineurin targets. Moreover, experiments with
calcineurin inhibitors FK506 and cyclosporin A (CsA) have
provided further insights into the role of calcineurin in metabolism
and b-cell function. CsA and FK506 inhibit calcineurin activity by
binding to regulatory proteins of the enzyme, Cyclophilin A and
FKBP-12 respectively [24]. Administration of CsA and FK506 to
rodents [25] or humans [26,27] induces hyperglycemia and
hypoinsulinemia. Complementary in vitro experiments in vitro using
insulinoma cells and human islets have demonstrated that CsA
and Fk506 reduce Insulin biosynthesis and secretion [28,29] [30].
While these studies demonstrated that calcineurin deficiency
resulted in b-cell failure and diabetes, it is unclear whether
increased glucose-induced Ca
2+ influx and subsequent calcineurin
activation will mimic the hypertrophic effects of chronic
depolarization on b-cell function and mass.
The experiments reported herein explored the role of sustained
activation of calcineurin activity in regulation of pancreatic b-cell
mass and function. To achieve this, we generated transgenic mice
overexpressing a constitutively active calcineurin mutant in b-cells
under the control of the rat insulin promoter. These mice
developed hyperglycemia and hypoinsulinemia as a result of
decreased b-cell mass and Insulin secretion. The changes in b-cell
mass resulted from decreased proliferation and augmented
apoptosis. The current work demonstrated that sustained
calcineurin hyperactivity negatively impacts b-cell growth and
function. These studies imply that calcineurin could mediate some
of the glucotoxic effects induced by chronic hyperglycemia in type
2 diabetes.
Methods
Generation of transgenic mice
The constitutively active calcineurin used for these experiments
lacks the regulatory domain of calcineurin A (CnMut) [31,32].
The calcineurin mutant was provided by Gerald R. Crabtree
(Stanford University School of Medicine) and was generated by
introducing a stop codon at nucleotide 1259 as described [31].
This sequence was inserted at the EcoRI site in a RIP-I/b-Globin
expression vector. This chimeric gene (caCn
RIP) was excised by
enzymatic digestion, purified, and microinjected into fertilized
eggs of C57Bl6 6 CBA mice according to standard technique.
Three transgenic founders (#167, #138 and #139) expressing the
caCn
RIP chimeric gene were generated in a C57Bl66CBA genetic
background. Founders were backcrossed to C57BL6J mice.
Experiments were performed on comparable mixed background.
Two lines exhibited a similar phenotype. The studies described
herein were performed on animals derived from the #138 line. All
procedures were approved by the Washington University Animal
Studies Committee.
MIN6 cell culture and adenoviral infection
MIN6 cells were maintained in DMEM (Gibco) as previously
described [33]. The cells were transduced either with a control
GFP or a constitutively active calcineurin adenovirus overnight at
an MOI of 19. The transduced cells were maintained in the media
for 48 hours before harvesting.
Immunoblotting
For western blot analysis, blots of isolated pancreatic islet lysates
and MIN6 cells were probed with antibodies against calcineurin A
(BD Biosciences), phospho Akt S473 (Cell Signaling) and tubulin
(Sigma). Protein obtained from islets (50 g; ,100 islets) were used
for each experiment. Briefly, islet lysates were separated by
electrophoresis on polyacrylamide gels and transferred to nitro-
cellulose or PVDF membranes (Bio-Rad). After blocking over-
night, membranes were incubated for 24 hours with primary
antibodies at the dilutions recommended by the manufacturer.
Immunoblotting experiments were performed at least three times
in duplicate.
Immunostaining, islet morphometry and analysis of
proliferation and apoptosis
Pancreata obtained from 12-week-old mice were used for
morphometry and immunohistochemistry. Immunostaining for
insulin, glucagon, somatostatin and pancreatic polypeptide cells
was performed as described [34,35]. The b-cell mass was
calculated by point counting morphometry from 5 insulin stained
sections (5 mm) separated by 200 mm using the NIH ImageJ
software (v1.43n freely available at http://rsb.info.nih. gov/ij/
index.html [36] as described [34,35]. Pancreata from neonates
were obtained during the first 12 hours of life. Proliferation was
assessed in insulin and Ki67 (Novocastra, Burlingame, CA) stained
sections as previously described [34]. Apoptosis was determined in
pancreatic sections using cleaved Caspase 3 (Cell Signaling) and
Insulin staining as described [35]. At least 1000 insulin stained
cells were counted for each animal.
Assessment of glucose metabolism and insulin secretion
Fasting blood samples were obtained after overnight fasting
from the tail vein. All the metabolic studies were performed in
male mice. Glucose was measured on whole blood using
AccuChek II glucometer (Roche Diagnostics, Indianapolis).
Plasma insulin levels were determined on 5 ml aliquots by using
a Rat Insulin ELISA kit (Crystal Chem, Chicago, Illinois). Glucose
tolerance tests were performed in 12-hour fasted animals by
injecting glucose (2 mg/g) intraperitoneally as described [34].
Islet isolation and in vitro insulin secretion
Islet isolation was accomplished by collagenase digestion and
differential centrifugation through Ficoll gradients using a modifi-
cation of procedures described previously for rat islets [34]. After
isolation, islets were hand picked and lysed in lysis buffer (Cell
Signaling, Beverly, Massachusetts). Insulin secretion in vitro was
assessed by static incubation of islets. After overnight culture in
RPMI media containing 5 mM glucose, islets of similar size from
caCn
RIP mice and wild-type mice were handpicked and pre-cultured
for an hour in Krebs-Ringer medium containing 2 mM glucose.
Groups of five islets in triplicate were incubated in Krebs-Ringer
medium containing either 2 mM glucose, 20 mM glucose, or
30 mM KCl, and incubated at 37uC. After 1-hour incubation,
medium was collected and stored at –20uC, after which insulin was
measured by RIA. Islet perifusion experiments were carried out as
described [37]. Briefly, groups of 80 were suspended in Bio-Gel P2
beads and perifused at 1 mL/min using a temperature-controlled
multi-chamber perifusion system (Cellex Biosciences, Minneapolis,
MN). Net hormone release responses of perifused cell columns to
treatments were quantified by integrating the baseline-subtracted
area under the curve during the treatment period. Each time point
was subtracted from the prepulse mean, defined as the average of
the three time points before the treatment period.
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All values are expressed as mean 6 SEM. Paired Student’s t test
was used for all comparisons. Differences were considered
statistically significant at p,0.05.
Results
Generation of mice expressing a constitutively active
form of calcineurin in b-cells
The constitutively active calcineurin mutant used for these
studies lacks the regulatory domain of calcineurin A (caCn) and
exhibits Ca
2+-independent constitutive phosphatase activity in vitro
and in vivo [31,32,38]. This was achieved by deleting the carboxy
terminal sequence including a fraction of the Calmodulin binding
domain and the auto inhibitory domain of calcineurin A as
described [31,32,38]. This sequence was inserted downstream of
the rat insulin I promoter sequence (caCn
RIP, Figure 1A). Two lines
with a similar expression levels and phenotypes were obtained.
The studies described herein were performed on animals derived
from one of these lines. Expression of the transgene in islet lysates
from WT and transgenic mice demonstrated expression of the
mutant protein (40 Kd band) only in caCn
RIP mice (Figure 1B). No
alterations in weight were observed in caCn
RIP mice suggesting that
there were no major abnormalities in appetite control by
expression of the transgene in the hypothalamus (data not shown).
caCn
RIP mice exhibit hyperglycemia
To determine the effects of constitutively active calcineurin in
islet b-cells on glucose metabolism, we examined random glucose
and insulin levels in 8–12 week-old mice. Random glucose levels
were higher in caCn
RIP mice (Figure 2A). caCn
RIP mice exhibited
concomitant hypoinsulinemia (Figure 2B). Intraperitoneal glucose
tolerance testing demonstrated that caCn
RIP mice displayed higher
glucose levels after 30 and 60 minutes after glucose injection
(Figure 2C). Similar glucose intolerance was observed in 12 week
old mice (Figure 2C). The glucose intolerance was also observed in
caCn
RIP females (Figure S1).
Overexpression of constitutively active calcineurin in
islets induces the second phase of insulin secretion
To begin to elucidate the mechanisms responsible for impaired
glucose tolerance in caCn
RIP mice, we assessed insulin secretion in
vivo and in vitro. Insulin levels in caCn
RIP mice were reduced relative
to those in WT mice after overnight fasting and did not increase
after glucose injection (Figure 3A). Insulin levels were lower in
caCn
RIP islets cultured in 2 mM glucose for 60 min (p,0.05, data
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Figure 1. Transgene construct and expression in islet lysates from WT and caCn
RIP mice. A. Domain structure of calcineurin A. The mutant
form including the first 1259 bp (400 amino acids) was subcloned into a vector containing the rat insulin promoter. B. Immunoblotting for calcineurin
using islet lysates from WT and caCn
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was similar in caCn
RIP mice (Figure 3B). Since calcineurin signaling
has been reported to modulate the different phases of Insulin
secretion [39], we performed islet perifusion experiments. Basal
Insulin secretion at 2 mM glucose before and after glucose
stimulation was decreased in caCn
RIP islets (Figure 3C). No
significant difference was observed in the first phase of Insulin
secretion (Figure 3C). Interestingly, the second phase of insulin
secretion was enhanced in caCn
RIP islets (Figure 3C). However, the
area under the curve for glucose stimulated Insulin secretion was
comparable (p.0.05, data not shown).
Pancreas morphometry on WT and caCn
RIP mice
Morphometric analysis was then performed to determine the
cause of altered glucose tolerance and Insulin secretion in caCn
RIP
mice. Staining for Insulin and a cocktail of antibodies for non b-
cells revealed that islets from caCn
RIP mice showed decreased size
and irregular shape (Figure 4A). Analysis of b-cell mass in 12-
week-old mice indicated that caCn
RIP mice exhibited more than a
50% reduction in b-cell mass (Figure 4B). To determine whether
this reduced mass was a developmental defect or acquired post-
natally, the b-cell mass in WT and caCn
RIP neonates was examined
and found to be not significantly different (Figure 4C). These
studies demonstrate that caCn
RIP mice are born with normal b-cell
mass and develop decrease in mass during the first 12 weeks of life.
Decrease in b-cell mass in caCn
RIP mice results from
decreased proliferation and increased apoptosis
We next examined whether the decrease in b-cell mass in
caCn
RIP mice was the result of decreased proliferation or increased
apoptosis. Analysis of proliferation performed by Ki67 staining
demonstrated that caCn
RIP mice exhibited decreased proliferation
(Figure 5A). caCn
RIP mice also displayed a concomitant increase in
apoptosis revealed by cleaved-caspase 3 staining (Figure 5B),
indicating that calcineurin affects both proliferation and apoptosis.
Discussion
The current studies extend our knowledge of the role of
calcineurin in pancreatic islet b-cells by examining the effects of
chronic activation of calcineurin on b-cell mass and function.
These experiments demonstrate that long-term activation of
calcineurin induces impaired glucose tolerance by alterations in
b-cell mass. We also show that activation of calcineurin signaling
negatively affects proliferation and survival of b-cells. These
morphological alterations resemble in part the phenotype of b-cells
exposed to chronic hyperglycemia and suggest that chronic
activation of calcineurin could be an important component of
the glucotoxic effect of hyperglycemia in type 2 diabetes and
possibly also explain the failure of these agents to control diabetes
after long-term therapy with this medication.
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Figure 2. RIP-CnMut mice have higher fed serum blood glucose compared to control littermates. Serum glucose (A) and Insulin (B)
concentrations in non-fasting 2–3 month old caCn
RIP mice (n=5) and control littermates (n=8). C. Intraperitoneal glucose tolerance tests in 8 and 12-
week old caCn
RIP mice (n=7) and control littermate (n=4) males as indicated (left and right panels; n=4). Results are expressed as mean 6 SEM.
*p ,0.05.
doi:10.1371/journal.pone.0011969.g002
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major disturbances in plasma glucose levels. A small fraction of the
animals developed frank diabetes making it difficult to maintain
the line. The abnormalities in glucose were associated with
decreased Insulin levels. Transgenic mice exhibited severe
impairment in glucose-induced Insulin secretion in vivo. The
severe defect in Insulin secretion in the context of 50% of normal
b-cell mass suggested the possibility that caCn
RIP mice might
exhibit some degree of impaired Insulin secretion. However, in vitro
Insulin secretion in response to glucose was similar in static
incubation and perifusion experiments (Figure 3). Islet perifusion
experiments showed that islets from caCn
RIP mice exhibited a
robust first phase of Insulin secretion implying that the readily
releasable pool was not significantly altered. Interestingly, we
observed a significant increase in the second phase of insulin
secretion suggesting that calcineurin may modulate events
associated with insulin granule trafficking [39]. The changes in
second phase of Insulin secretion could be explained in part by
dephosphorylation of Kinesin Heavy chain (KHC) on b-granules.
Phosphorylation of KHC inhibits the binding of granules to
microtubules and prevents the transport towards the cell
membrane [39,40]. In contrast, inhibition of calcineurin-mediated
KHC dephosphorylation using inhibitors and adenoviruses
inhibits second phase of insulin secretion [39]. In summary the
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Figure 3. Transgenic mice expressing calcineurin showed altered insulin secretion. A. Glucose stimulated insulin secretion in vivo assessed
by intraperitoneal glucose injection. B. Static Insulin secretion in isolated islets from 8–12 week old WT and caCn
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PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e11969Figure 4. Pancreas morphometry on WT and caCn
RIP mice. A. Immunostaining for Insulin and non b-cells in pancreas from WT and caCn
RIP
mice. Images presented were obtained at different magnifications (Upper panel 10x and lower panel 40x). Assessment of b-cell mass using point-
counting morphometry in WT and caCn
RIP mice at 12 weeks of age (B) and neonates (C). Results are mean 6 SEM (n=4). * p,0.05.
doi:10.1371/journal.pone.0011969.g004
Calcineurin and b Cells
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reconcile but it is possible that the stress of the isolation procedure
and the selection of islets for perifusion are biased to favor the
availability and collection of healthier islets and these islets are not
completely representative of the integrated response obtained in in
vivo experiments. It is also probable that activation of calcineurin in
neurons could contribute to the regulation of in vivo insulin
secretion in this model. However, we believe that this is less likely
due to lack of evidence of central expression of the promoter used
for these experiments.
Decreased b-cell mass was an important component responsible
for the hyperglycemic phenotype in caCn
RIP mice. The diminished
b-cell mass was caused by reduced proliferation and increased
apoptosis. The mechanisms involved in the regulation of b-cell
cycle by calcineurin are partially understood. Heit et al. showed
that transgenic activation of NFATc1 in b-cells induces prolifer-
ation by inducing Cyclin D and Cdk4 levels [23]. This suggests
that the decreased proliferation observed by activation of
calcineurin is mediated in an NFATc1-independent manner. It
is important to note that NFAT transcription factors are not the
only calcineurin-downstream substrates and other calcineurin-
regulated proteins such as Map Kinase Phosphatase 1 (MKP1)
[41], Cdk4 [42,43], PKA, NO synthase and the co-activator
TORC could also be involved [44,45,46]. To this end, we have
demonstrated that glucose and KCl-induced depolarization
induces MKP1 expression in a calcineurin-dependent manner
(data not shown). Therefore, increased MKP1 can inhibit
Mitogen-Activated Protein Kinase (MAPK) activation and subse-
quent cell cycle progression. In summary, the current findings are
consistent with a negative effect of calcineurin on cell cycle
progression by activation of downstream signaling targets other
than NFATc1. The loss of the transgenic line prevents us from
pursuing some of these avenues.
The decreased b-cell mass in caCn
RIP mice could also be
explained in part by augmented apoptosis. The role of
calcineurin in apoptosis has been extensively examined in
neurons and lymphoid tissues, among others [16,47,48,49]. In
b-cells, inhibition of calcineurin is protective against apoptosis
induced by proinflammatory cytokines and dexamethasone
[47,50,51]. The mechanisms involved in apoptosis observed in
caCn
RIP mice could be multifactorial. As demonstrated in other
systems, including b-cells, calcineurin-mediated dephosphoryla-
tion and activation of the pro-apoptotic Bcl-2 family protein Bad
is a major component of apoptosis induced by elevated Ca
2+/
Calcienurin signaling [49,50,51]. Recent experiments showed
that calcineurin decreased Akt signaling by dephoshorylation of
S473 [52]. However, Akt
S473 phosphorylation was not altered in
MIN6 cells expressing a constitutively active calcineurin suggest-
ing that this mechanism is not likely to play a role (Figure S2). In
summary, our studies suggest that the genetic activation of
calcineurin signaling reduces b-cell mass by induction of
apoptosis. It is unclear at this point if these calcineurin effects
are mediated by NFAT.
In summary, the present work shows that chronic activation of
calcineurin signaling regulates survival and proliferation of b-cells.
These studies together with those obtained in mice with deletion of
Cnb1 in b-cells [23] suggest that calcineurin signaling is a major
component of the effects induced by glucose depolarization/Ca
2+
influx. Similar pattern of responses derived from apoptotic
responses to intracellular Ca
2+ concentration in neurons have
led to the development of the Ca
2+ set-point hypothesis [16]. The
results of the present study suggest that persistent activation of
calcineurin signaling could be an important component respon-
sible for the responses to chronic depolarization.
Supporting Information
Figure S1 A Random blood glucose levels in 8-week-old females
(n=4). B. Glucose tolerance in 8-week-old females. Intraperitoneal
glucose tolerance tests was performed in 8 and 12-week old
caCnRIP mice and littermates females (B) (n=4).
Found at: doi:10.1371/journal.pone.0011969.s001 (0.40 MB EPS)
Figure S2 Western blots on MIN6 cells transduced with a
control (GFPAdv) or constitutively active calcineurin (caCnAdv)
adenovirus. Immunoblotting for Calcineurin (A) or phospho Akt
(473) (B) and tubulin. Expression levels were normalized to tubulin
and quantified on the right. Results are mean 6 SEM (n=4).
*p ,0.05.
Found at: doi:10.1371/journal.pone.0011969.s002 (0.71 MB EPS)
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